Are medical comorbid conditions of bipolar disorder due to immune dysfunction?

Acta Psychiatrica Scandinavica

Volumn 132, Issue 3, 2015, Pages 180-191

  Rosenblat, J D ^a,b   Mcintyre, R S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Autoimmune disease; Bipolar disorder; Cardiovascular disease; Diabetes; Inflammation; Obesity

Indexed keywords

ACUTE PHASE PROTEIN; ANTIINFLAMMATORY AGENT; CELL ADHESION MOLECULE; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; REACTIVE OXYGEN METABOLITE; SOLUBLE RECEPTOR OF TUMOR NECROSIS FACTOR ALPHA TYPE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; CYTOKINE;

ARTICLE; AUTOIMMUNE DISEASE; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COGNITION; COMORBIDITY; DISEASE ASSOCIATION; EMBASE; EPIDEMIOLOGICAL DATA; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INFLAMMATION; INFLAMMATORY DISEASE; MAJOR DEPRESSION; MANIA; MEDLINE; META ANALYSIS (TOPIC); METABOLIC DISORDER; MOOD CHANGE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT INDICATION; CEREBROSPINAL FLUID; COMPLICATION; IMMUNOLOGY; PSYCHOLOGY;

BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; COMORBIDITY; CYTOKINES; HUMANS;

EID: 84938751162     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12414     Document Type: Article

References (90)

1. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002;68:167-181.
2. Young AH, Grunze H. Physical health of patients with bipolar disorder. Acta Psychiatr Scand Suppl 2013;442:3-10.
3. Klumpers UM, Boom K, Janssen FM, Tulen JH, Loonen AJ. Cardiovascular risk factors in outpatients with bipolar disorder. Pharmacopsychiatry 2004;37:211-216.
4. McIntyre RS, Danilewitz M, Liauw SS et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010;126:366-387.
5. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005;17:83-93.
6. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58:844-850.
7. Perugi G, Quaranta G, Belletti S et al. General medical conditions in 347 bipolar disorder patients: clinical correlates of metabolic and autoimmune-allergic diseases. J Affect Disord 2014;170C:95-103.
8. Swartz HA, Fagiolini A. Cardiovascular disease and bipolar disorder: risk and clinical implications. J Clin Psychiatry 2012;73:1563-1565.
9. Vancampfort D, Vansteelandt K, Correll CU et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013;170:265-274.
10. De HM, Correll CU, Bobes J et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52-77.
11. Gurpegui M, Martinez-Ortega JM, Gutierrez-Rojas L, Rivero J, Rojas C, Jurado D. Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Prog Neuropsychopharmacol Biol Psychiatry 2012;37:169-175.
12. Liu CS, Carvalho AF, Mansur RB, McIntyre RS. Obesity and bipolar disorder: synergistic neurotoxic effects? Adv Ther 2013;30:987-1006.
13. McElroy SL, Keck PE Jr. Obesity in bipolar disorder: an overview. Curr Psychiatry Rep 2012;14:650-658.
14. Barbosa IG, Machado-Vieira R, Soares JC, Teixeira AL. The immunology of bipolar disorder. NeuroImmunoModulation 2014;21:117-122.
15. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009;70:1078-1090.
16. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007;104:91-95.
17. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. Philadelphia, PA: Elsevier Saunders, 2012. 545 p.
18. Wang M, Jiang L, Monticone RE, Lakatta EG. Proinflammation: the key to arterial aging. Trends Endocrinol Metab 2014;25:72-79.
19. Purkayastha S, Cai D. Neuroinflammatory basis of metabolic syndrome. Mol Metab 2013;2:356-363.
20. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2014;53:23-34.
21. McNamara RK, Lotrich FE. Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target? Expert Rev Neurother 2012;12:1143-1161.
22. Barbosa IG, Bauer ME, Machado-Vieira R, Teixeira AL. Cytokines in bipolar disorder: paving the way for neuroprogression. Neural Plast 2014;2014:360481.
23. Barbosa IG, Rocha NP, Bauer ME et al. Chemokines in bipolar disorder: trait or state? Eur Arch Psychiatry Clin Neurosci 2013;263:159-165.
24. Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun 2009;23:1079-1082.
25. Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, Leu SJ. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol 2004;150:116-122.
26. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
27. Eller T, Vasar V, Shlik J, Maron E. The role of IL-2 and soluble IL-2R in depression and antidepressant response. Curr Opin Investig Drugs 2009;10:638-643.
28. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013;246:199-229.
29. Soderlund J, Olsson SK, Samuelsson M et al. Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder. J Psychiatry Neurosci 2011;36:114-118.
30. Lindqvist D, Janelidze S, Hagell P et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009;66:287-292.
31. Olsson SK, Sellgren C, Engberg G, Landen M, Erhardt S. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord 2012;14:719-726.
32. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010;15:384-392.
33. Bezchlibnyk YB, Wang JF, McQueen GM, Young LT. Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. J Neurochem 2001;79:826-834.
34. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 2005;29:891-909.
35. Capuron L, Neurauter G, Musselman DL et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 2003;54:906-914.
36. Reichenberg A, Yirmiya R, Schuld A et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445-452.
37. Wright CE, Strike PC, Brydon L, Steptoe A. Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun 2005;19:345-350.
38. Grigoleit JS, Kullmann JS, Wolf OT et al. Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PLoS ONE 2011;6:e28330.
39. Alavi M, Grebely J, Matthews GV et al. Effect of pegylated interferon-alpha-2a treatment on mental health during recent hepatitis C virus infection. J Gastroenterol Hepatol 2012;27:957-965.
40. Raison CL, Broadwell SD, Borisov AS et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005;19:23-27.
41. Udina M, Castellvi P, Moreno-Espana J et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012;73:1128-1138.
42. Capuron L, Ravaud A, Gualde N et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001;26:797-808.
43. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002;7:468-473.
44. Stertz L, Magalhaes PV, Kapczinski F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr Opin Psychiatry 2013;26:19-26.
45. Arango V, Underwood MD, Mann JJ. Serotonin brain circuits involved in major depression and suicide. Prog Brain Res 2002;136:443-453.
46. Beishuizen A, Thijs LG. Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotoxin Res 2003;9:3-24.
47. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009;66:407-414.
48. McAllister-Williams RH, Ferrier IN, Young AH. Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychol Med 1998;28:573-584.
49. Murphy BE. Steroids and depression. J Steroid Biochem Mol Biol 1991;38:537-559.
50. Ekdahl CT. Microglial activation - tuning and pruning adult neurogenesis. Front Pharmacol 2012;3:41.
51. Harry GJ, Kraft AD. Microglia in the developing brain: a potential target with lifetime effects. Neurotoxicology 2012;33:191-206.
52. Park KM, Bowers WJ. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 2010;22:977-983.
53. Brietzke E, Stertz L, Fernandes BS et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009;116:214-217.
54. Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord 2010;12:638-646.
55. Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009;61:822-829.
56. Kupka RW, Nolen WA, Post RM et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 2002;51:305-311.
57. Hsu CC, Chen SC, Liu CJ et al. Rheumatoid arthritis and the risk of bipolar disorder: a nationwide population-based study. PLoS ONE 2014;9:e107512.
58. Edwards LJ, Constantinescu CS. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler 2004;10:575-581.
59. Calkin C, van de Velde C, Ruzickova M et al. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord 2009;11:650-656.
60. Jafferany M. Lithium and psoriasis: what primary care and family physicians should know. Prim Care Companion J Clin Psychiatry 2008;10:435-439.
61. Han C, Lofland JH, Zhao N, Schenkel B. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol 2011;10:843-850.
62. Church TS, Barlow CE, Earnest CP, Kampert JB, Priest EL, Blair SN. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol 2002;22:1869-1876.
63. Fenton WS, Stover ES. Mood disorders: cardiovascular and diabetes comorbidity. Curr Opin Psychiatry 2006;19:421-427.
64. Lilliker SL. Prevalence of diabetes in a manic-depressive population. Compr Psychiatry 1980;21:270-275.
65. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999;156:1417-1420.
66. Kaidanovich-Beilin O, Cha DS, McIntyre RS. Crosstalk between metabolic and neuropsychiatric disorders. F1000 Biol Rep 2012;4:14.
67. Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 2013;30:297-306.
68. Gans RO. The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Med Clin North Am 2006;90:573-591.
69. Mansur RB, Cha DS, Woldeyohannes HO et al. Diabetes mellitus and disturbances in brain connectivity: a bidirectional relationship? NeuroMol Med 2014;16:658-668.
70. Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry 2008;13:918-929.
71. Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 2011;25:1035-1059.
72. Soczynska JK, Kennedy SH, Woldeyohannes HO et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. NeuroMol Med 2011;13:93-116.
73. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007;89:91-100.
74. Fountoulakis KN. Refractoriness in bipolar disorder: definitions and evidence-based treatment. CNS Neurosci Ther 2012;18:227-237.
75. Singh JA, Furst DE, Bharat A et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-639.
76. Green GA. Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone 2001;3:50-60.
77. Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol 2014;29:216-223.
78. Nery FG, Monkul ES, Hatch JP et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008;23:87-94.
79. Levine J, Cholestoy A, Zimmerman J. Possible antidepressant effect of minocycline. Am J Psychiatry 1996;153:582.
80. Soczynska JK, Mansur RB, Brietzke E et al. Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res 2012;235:302-317.
81. Calder PC. The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukot Essent Fatty Acids 2008;79:101-108.
82. Gertsik L, Poland RE, Bresee C, Rapaport MH. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol 2012;32:61-64.
83. Jazayeri S, Tehrani-Doost M, Keshavarz SA et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 2008;42:192-198.
84. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913-919.
85. Berger GE, Proffitt TM, McConchie M et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry 2007;68:1867-1875.
86. Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL. Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr 2009;63:1037-1040.
87. Stoll AL, Severus WE, Freeman MP et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56:407-412.
88. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991;54:438-463.
89. Kohler O, Benros ME, Nordentoft M et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014;71:1381-1391.
90. Raison CL, Rutherford RE, Woolwine BJ et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013;70:31-41.